A Phase 3 interventional study of Tenecteplase 0.18 mg/kg and Tenecteplase 0.25 mg/kg in Acute Ischemic Stroke and Minor Ischemic Stroke, sponsored by Shandong Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Shandong Provincial Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.
Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 11th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 25 of the 31 other live ones, and was the 58th registered.
2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.
Browse Ischemic Stroke studies →32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Yongjun Wang · Sites in China
Ages 18+
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
By country, each count listing its studies:
Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 43 · Phase 4 5
First in 2012; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 1,324 is above the median of 120 across 1,785 interventional studies indexed under Ischemic Stroke.
Median enrollment 466 across the 59 interventional studies. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 59 have an industry lead sponsor. The 10 most frequent:
Shandong Provincial Hospital is the lead sponsor of 64 studies on the registry; 26 are open to participants now.
Shandong Provincial Hospital has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies testing tenecteplase in Ischemic Stroke that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07047014Phase 3Beijing Tiantan HospitalAdvancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke | 2027-03-30 |
| NCT07073469Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial | 2027-08-01 |
| NCT07201688Phase 3CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 59 studies testing tenecteplase in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.
The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.
Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.
Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Drug: Tenecteplase 0.18 mg/kg
Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Drug: Tenecteplase 0.25 mg/kg
Drug page: Tenecteplase
Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Also known as: rhTNK-tPA, Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection
Drug page: Tenecteplase
Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.
Also known as: rhTNK-tPA, Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-1 indicates no significant disability.
Time frame: 90 ± 7 days after randomization
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-2 indicates functional independence.
Time frame: 90 ± 7 days after randomization
Distribution of Modified Rankin Scale (mRS) Scores
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. The distribution across all seven categories (0-6) will be assessed.
Time frame: 90 ± 7 days after randomization
Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. An NIHSS score of 0-1 indicates no or minimal neurological deficits.
Time frame: 22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological worsening is defined as an increase of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.
Time frame: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological improvement is defined as a decrease of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.
Time frame: Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a COSMOS score Grade of 0-1
The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence or worse), with higher scores indicating worse outcomes. The proportion of participants with a COSMOS grade of 0-1 will be assessed.
Time frame: 90 ± 7 days after randomization
COSMOS Score
The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), with higher scores indicating worse outcomes. The distribution of COSMOS grades from 0 to 6 at 90 days will be assessed.
Time frame: 90 ± 7 days after randomization
Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS
The EuroQol Five-Dimension Three-Level Questionnaire (EQ-5D-3L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels, ranging from 1 (no problems) to 3 (extreme problems or inability to perform the activity), with higher levels indicating worse health status. The accompanying EuroQol Visual Analogue Scale (EQ VAS) assesses self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better health status.
Time frame: 90 ± 7 days after randomization
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours
Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death.
Time frame: Within 36 hours after study drug administration
Incidence of Any Intracranial Hemorrhage Within 36 Hours
Any intracranial hemorrhage is defined as the presence of intracranial bleeding detected by brain computed tomography (CT) or magnetic resonance imaging (MRI), regardless of whether neurological deterioration or clinical symptoms are present. Both symptomatic and asymptomatic intracranial hemorrhages are included.
Time frame: Within 36 hours after study drug administration
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days
Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. Events occurring within 7 days after study drug administration will be assessed.
Time frame: Within 7 days after study drug administration
Incidence of Major Extracranial Bleeding According to ISTH Criteria
Major extracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as bleeding outside the cranium meeting at least one of the following: fatal bleeding; symptomatic bleeding in a critical extracranial area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome; a decrease in hemoglobin of ≥2 g/dL; or transfusion of ≥2 units of whole blood or red blood cells.
Time frame: Within 7 days after study drug administration
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6
The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 5-6 indicates severe disability or death.
Time frame: 90 ± 7 days after randomization
All-Cause Mortality
Time frame: Within 90 days after randomization
Proportion of Participants Experiencing at Least One Adverse Event
Time frame: Within 90 days after study drug administration
Proportion of Participants Experiencing at Least One Serious Adverse Event
Time frame: Within 90 days after study drug administration
Started Oct 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 30 months is close to that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase
Shandong Provincial Hospital